Previous 10 | Next 10 |
UroGen Pharma Ltd. (URGN) Q3 2019 Earnings Conference Call November 12, 2019, 08:30 AM ET Company Participants Catherine Bechtold - Senior Director of IR Elizabeth Barrett - President and CEO Mark Schoenberg - Chief Medical Officer Peter Pfreundschuh - CFO Stephen Mullennix -...
UroGen Pharma (NASDAQ: URGN ): Q3 GAAP EPS of -$1.06 beats by $0.21 . More news on: UroGen Pharma Ltd., Earnings news and commentary, Healthcare stocks news, Read more ...
Completed Submission of New Drug Application (NDA) to U.S. FDA for UGN-101 in Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Exclusive Worldwide License Agreement with Agenus to Advance Treatment of High-Grade Urinary Tract Cancers in Combination with UGN-201 Conf...
UroGen to Develop and Commercialize Zalifrelimab (AGEN1884, anti-CTLA-4 antibody) with UGN-201 for High-Grade Non-Muscle Invasive Bladder Cancer UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of u...
Conference Call and Webcast Scheduled for Tuesday, November 12, 2019 at 8:30 AM ET UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report third quarter 2019 financial results on Tuesday, November 12, 2019, prior to the open of the market. The announcement will be followed...
Over the past month, lots of biotech stocks have been hammered for reasons that aren't always clear. The market has made mistakes in the past and investors are right to assume it may have gone too far with some of these unfortunate companies. Can any of these beaten-down drugmakers bounce back?...
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it will present at the following conference in October: 2019 Cantor Global Healthcare Conference Wednesday, October 2 nd ...
After the release of the data, I thought that there was no need to continue this topic, as my expectations were confirmed. But the fact is that, in view of some speculations on this topic, attempts to interpret article conclusions differently, I would like to give my final assessment, taking i...
Shares of UroGen Pharma (NASDAQ: URGN) fell over 19% on Wednesday and another 12% on Thursday after a short-seller published an article on Seeking Alpha arguing that the company was overvalued at a market cap of $730 million. There were two main arguments. First, the short-seller thinks t...
UroGen (NASDAQ: URGN ) is a clinical stage biopharmaceutical company involved in the development of new treatment options with a focus on uro-oncology. In this article, I will try to explain my skepticism on the company's new drug candidates. The company’s new approach is based on t...
News, Short Squeeze, Breakout and More Instantly...
2024-07-15 04:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-25 07:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ord...